liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression
IRCCS Osped San Raffaele, Italy.
IRCCS Osped San Raffaele, Italy.
IRCCS Osped San Raffaele, Italy.
IRCCS Osped San Raffaele, Italy.
Show others and affiliations
2014 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 50, no 14, 2478-2488 p.Article in journal (Refereed) Published
Abstract [en]

Mesenchymal stem cells (MSC) as vehicles of therapeutic genes represent a unique tool to activate drugs within a neoplastic mass due to their property to home and engraft into tumours. In particular, MSC expressing the cytosine deaminase:: uracil phosphoribosyltransferase (CD-MSC) have been previously demonstrated to inhibit growth of subcutaneous prostate cancer xenografts thanks to their ability to convert the non-toxic 5-fluorocytosine into the antineoplastic 5-fluorouracil. Since both the immune system and the tumour microenvironment play a crucial role in directing cancer progression, in order to advance towards clinical applications, we tested the therapeutic potential of this approach on animal models that develop autochthonous prostate cancer and preserve an intact immune system. As cell vectors, we employed adipose-tissue and bone-marrow MSC. CD-MSC toxicity on murine prostate cancer cells and tumour tropism were verified in vitro and ex-vivo before starting the preclinical studies. Magnetic Resonance Imaging was utilised to follow orthotopic tumour progression. We demonstrated that intravenous injections of CD-MSC cells, followed by intraperitoneal administration of 5-fluorocytosine, caused tumour regression in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model, which develops aggressive and spontaneous prostate cancer. These results add new insights to the therapeutic potential of specifically engineered MSC in prostate cancer disease.

Place, publisher, year, edition, pages
Elsevier , 2014. Vol. 50, no 14, 2478-2488 p.
Keyword [en]
Mesenchymal stem cells; Prodrug activating enzymes; Prostate cancer; TRAMP mice; Magnetic resonance imaging
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-111273DOI: 10.1016/j.ejca.2014.06.014ISI: 000341449200012PubMedID: 25060826OAI: oai:DiVA.org:liu-111273DiVA: diva2:755545
Note

Funding Agencies|Sanofi; Associazione Amici di URI onlus; Slovak League against Cancer

Available from: 2014-10-14 Created: 2014-10-14 Last updated: 2017-12-05

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Hedlund, Petter

Search in DiVA

By author/editor
Hedlund, Petter
By organisation
Division of Drug ResearchFaculty of Health SciencesDepartment of Clinical Pharmacology
In the same journal
European Journal of Cancer
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 199 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf